Back to resultsReaching Better Health Study: A Website to Improve Type 2 Diabetes Self-Management (REACH)
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Health & Wellness Website
Control Arm
Sponsored by
About this trial
This is an interventional supportive care trial for Diabetes Mellitus, Type 2 focused on measuring Medication Adherence, Self-efficacy, Behavior, Diabetes, Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Patient is a current patient in the Penn Medicine outpatient healthcare system
- Patient's Primary Care Physician (PCP) or Endocrinologist is a Penn Medicine provider
- Patient has a 12 month history of healthcare utilization in the Penn Medicine system (in-office PCP/endocrinologist visits)
- Patient has complete data (ICD-10 code for Type 2 diabetes diagnosis, date of diagnosis, name and mailing address information) in the Penn Data Warehouse
- Patient is diagnosed with Type II Diabetes as indicated by ICD-10 Codes: E11.** (including any newly diagnosed)
- Patients' HbA1c was ≥8.0% in last 6 months (if more than one A1c result present in record, most recent measurement assessed)
- Patient can read and understand English well enough to complete study tasks.
- Patient has regular access to a telephone
- Patient has at least bi-weekly access to internet and email
- Patient agrees to release their medical record information to Children's Hospital of Philadelphia research team
Exclusion Criteria:
- Patient is deceased
- Patient has indicated "Do Not Solicit for Research" in medical record
- Patient is less than 18 years of age
- Patient is older than 75 years old
- Patient uses an insulin pump or injectable insulin to treat/manage their diabetes.
- Patient is non-English speaking
- Patient does not have HbA1c% in chart from last 6 months
- Patients' HbA1c in last 6 months is <8.0%
- Patient is currently taking medications that can raise glucose levels, such as steroids
- Patient has a history of cognitive disorders, mental illness, and/or cognitive impairment that may impact their ability to use an online website, including, dementia, Alzheimer's disease, Parkinson's disease, traumatic brain or head injury, and psychosis
- Patient has history of Heart Failure (included Chronic Heart Disease, Chronic Heart Failure) and/or Chronic Kidney Disease, and has had other serious cardiovascular conditions (e.g, heart attack or stroke) in the last 6 months
- Patient has history of endocrine gland cancers or pancreatic cancers
- Patient is undergoing chemotherapy or immunotherapy treatment in last 6 months
- Patient's medical record contains ICD-10 Code for Type I diabetes diagnosis.
Patient's medical record contains ICD-10 Code for pregnancy-related diabetes:
- 024.419 (gestational diabetes)
- 024.419 (antepartum gestational diabetes)
- Z79.4 (type II long term insulin use)
- 024.91x (pregnant women who are diabetic)
- Patient is Pre-diabetic or borderline Type 2 diabetic
- Patient is pregnant or lactating
- Patient's electronic medical history data is not available through Penn Medicine's electronic medical record and/or is not complete in Penn Data Store
- Patients who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
Health & Wellness Website
Control Arm
Arm Description
Subjects will receive access to an interactive health & wellness website for 6 months. The site aims to provide patients with information, tools, and resources to manage their chronic condition (e.g., Type 2 diabetes). The website will send subjects emails with tips to help them take better care of their diabetes, such as how to track diet and exercise habits and how to cook healthy meals. The study researchers will keep track of how many times subjects access the website and which parts of the site are most commonly viewed. Intervention subjects will receive questionnaires assessing engagement and satisfaction with the website. Subjects will also complete questionnaires at baseline and 2, 4, and 6 months post-baseline.
Subjects in the control arm will continue with standard diabetes care without getting access to the intervention website. Subjects will also complete questionnaires at baseline and 2, 4, and 6 months post-baseline. Control subjects will be granted access to the health & wellness website after the study is completed.
Outcomes
Primary Outcome Measures
Change in Diabetes Self-Efficacy Scale Score from Baseline to 4 Months
The validated Diabetes Self-Efficacy Scale (Lorig et al., 2009) assesses how confident one is in doing certain activities related to diabetes management. There are 8 items in this measure with each one pertaining to a different activity. Each item is rated on a continuous scale of 1 to 10, 1 being not at all confident and 10 being totally confident. The score for each item is the number circled and higher value score indicates greater self-efficacy.
Secondary Outcome Measures
Change in Diabetes Knowledge Test Score from Baseline to 4 Months
This is a 14 item assessment, measuring general diabetes knowledge, was validated among Type 1 and Type 2 adult diabetics, Cronbach's α = 0.71. Each item is a multiple choice question, with options A-D. For scoring, the total number of questions answered correctly is calculated. The higher the score on the test, the greater knowledge one has about diabetes.
Change in Self-Efficacy Scale Score for Managing Chronic Disease from Baseline to 4 Months
This measure assesses how confident one is when performing various activities related to chronic disease management. There are 6 items on this scale with each one pertaining to a different activity. Each item is rated on a continuous scale of 1 to 10, with 1 being not at all confident and 10 being totally confident. The overall score for the measure is the average value of all the items. A higher score indicates a greater self-efficacy.
Change in glycated haemoglobin (HbA1c) from Baseline to 6 Months
By measuring glycated haemoglobin (HbA1c), clinicians are able to get an overall picture of what average blood sugar levels have been over a period of weeks/months. For people with diabetes this is important as the higher the HbA1c, the greater the risk of developing diabetes-related complications.
Full Information
NCT ID
NCT02757937
First Posted
April 25, 2016
Last Updated
December 13, 2018
Sponsor
Children's Hospital of Philadelphia
Collaborators
Merck Sharp & Dohme LLC, University of Pennsylvania
1. Study Identification
Unique Protocol Identification Number
NCT02757937
Brief Title
Reaching Better Health Study: A Website to Improve Type 2 Diabetes Self-Management
Acronym
REACH
Official Title
Study to Measure Merck Engage Usability and Conduct Outcomes Testing
Study Type
Interventional
2. Study Status
Record Verification Date
December 2018
Overall Recruitment Status
Completed
Study Start Date
May 2016 (undefined)
Primary Completion Date
December 31, 2017 (Actual)
Study Completion Date
December 31, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Children's Hospital of Philadelphia
Collaborators
Merck Sharp & Dohme LLC, University of Pennsylvania
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Diabetes is one of the most common chronic illnesses among adults in the United States. Internet-based interventions and health promotion websites for patients with Type 2 Diabetes are typically low-cost, easily accessible, and attractive. The purpose of this study is to determine whether participants' utilization of a health & wellness website focused on diabetes self-management increases participants' self-reported self-efficacy toward managing their Type 2 Diabetes through behavior change and self-reported medication adherence compared to standard care.
Detailed Description
Diabetes is one of the most common chronic illnesses among adults in the United States. Merck & Co., Inc. has produced an innovative website to engage adult patients in chronic illness self-management and medication adherence. Internet-based interventions and health promotion websites for patients are typically low-cost, easily accessible, and attractive. However, there is a growing need for improved measurement, implementation and evaluation of online health interventions to ensure patient engagement and produce more significant behavior change that can impact patients' health over the long term.
The primary objective of this study is to determine whether utilization of the health and wellness website increases participants' self-reported self-efficacy toward managing their Type 2 Diabetes through behavior change and self-reported medication adherence.
This study comprises a randomized controlled trial utilizing the website as the self-management support intervention. There is no interventional medical treatment, and no change in patients' medical care. In collaboration with University of Pennsylvania, potential participants will be identified and recruited from the Penn Medicine outpatient population based on specific inclusion/exclusion criteria. Participants will remain in the study for 6 months.
Participants will be randomly assigned to the intervention or control condition (no exposure). Those in the intervention arm will have access to health & wellness website for nine months post enrollment. Online surveys will be delivered during this nine month period. Primary outcomes will be baseline-to-two month and baseline-to-4 month changes in diabetes management self-efficacy scores as measured by the Diabetes Self-Efficacy Scale.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Medication Adherence, Self-efficacy, Behavior, Diabetes, Diabetes Mellitus
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
513 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Health & Wellness Website
Arm Type
Experimental
Arm Description
Subjects will receive access to an interactive health & wellness website for 6 months. The site aims to provide patients with information, tools, and resources to manage their chronic condition (e.g., Type 2 diabetes). The website will send subjects emails with tips to help them take better care of their diabetes, such as how to track diet and exercise habits and how to cook healthy meals. The study researchers will keep track of how many times subjects access the website and which parts of the site are most commonly viewed. Intervention subjects will receive questionnaires assessing engagement and satisfaction with the website. Subjects will also complete questionnaires at baseline and 2, 4, and 6 months post-baseline.
Arm Title
Control Arm
Arm Type
Other
Arm Description
Subjects in the control arm will continue with standard diabetes care without getting access to the intervention website. Subjects will also complete questionnaires at baseline and 2, 4, and 6 months post-baseline. Control subjects will be granted access to the health & wellness website after the study is completed.
Intervention Type
Behavioral
Intervention Name(s)
Health & Wellness Website
Intervention Description
Educational website for patients with chronic disease (i.e., Type 2 diabetes, asthma, high blood pressure, high cholesterol). The website is a free interactive resource to help patients manage their health condition(s) each day and to help them achieve their goals. It is a multichannel health and wellness platform to help patients adhere to their treatment and care plans between office visits.
Intervention Type
Other
Intervention Name(s)
Control Arm
Intervention Description
Continue with standard diabetes care without getting access to the intervention website.
Primary Outcome Measure Information:
Title
Change in Diabetes Self-Efficacy Scale Score from Baseline to 4 Months
Description
The validated Diabetes Self-Efficacy Scale (Lorig et al., 2009) assesses how confident one is in doing certain activities related to diabetes management. There are 8 items in this measure with each one pertaining to a different activity. Each item is rated on a continuous scale of 1 to 10, 1 being not at all confident and 10 being totally confident. The score for each item is the number circled and higher value score indicates greater self-efficacy.
Time Frame
Baseline to 4 months
Secondary Outcome Measure Information:
Title
Change in Diabetes Knowledge Test Score from Baseline to 4 Months
Description
This is a 14 item assessment, measuring general diabetes knowledge, was validated among Type 1 and Type 2 adult diabetics, Cronbach's α = 0.71. Each item is a multiple choice question, with options A-D. For scoring, the total number of questions answered correctly is calculated. The higher the score on the test, the greater knowledge one has about diabetes.
Time Frame
Baseline to 4 months
Title
Change in Self-Efficacy Scale Score for Managing Chronic Disease from Baseline to 4 Months
Description
This measure assesses how confident one is when performing various activities related to chronic disease management. There are 6 items on this scale with each one pertaining to a different activity. Each item is rated on a continuous scale of 1 to 10, with 1 being not at all confident and 10 being totally confident. The overall score for the measure is the average value of all the items. A higher score indicates a greater self-efficacy.
Time Frame
Baseline to 4 Months
Title
Change in glycated haemoglobin (HbA1c) from Baseline to 6 Months
Description
By measuring glycated haemoglobin (HbA1c), clinicians are able to get an overall picture of what average blood sugar levels have been over a period of weeks/months. For people with diabetes this is important as the higher the HbA1c, the greater the risk of developing diabetes-related complications.
Time Frame
Baseline to 6 Months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient is a current patient in the Penn Medicine outpatient healthcare system
Patient's Primary Care Physician (PCP) or Endocrinologist is a Penn Medicine provider
Patient has a 12 month history of healthcare utilization in the Penn Medicine system (in-office PCP/endocrinologist visits)
Patient has complete data (ICD-10 code for Type 2 diabetes diagnosis, date of diagnosis, name and mailing address information) in the Penn Data Warehouse
Patient is diagnosed with Type II Diabetes as indicated by ICD-10 Codes: E11.** (including any newly diagnosed)
Patients' HbA1c was ≥8.0% in last 6 months (if more than one A1c result present in record, most recent measurement assessed)
Patient can read and understand English well enough to complete study tasks.
Patient has regular access to a telephone
Patient has at least bi-weekly access to internet and email
Patient agrees to release their medical record information to Children's Hospital of Philadelphia research team
Exclusion Criteria:
Patient is deceased
Patient has indicated "Do Not Solicit for Research" in medical record
Patient is less than 18 years of age
Patient is older than 75 years old
Patient uses an insulin pump or injectable insulin to treat/manage their diabetes.
Patient is non-English speaking
Patient does not have HbA1c% in chart from last 6 months
Patients' HbA1c in last 6 months is <8.0%
Patient is currently taking medications that can raise glucose levels, such as steroids
Patient has a history of cognitive disorders, mental illness, and/or cognitive impairment that may impact their ability to use an online website, including, dementia, Alzheimer's disease, Parkinson's disease, traumatic brain or head injury, and psychosis
Patient has history of Heart Failure (included Chronic Heart Disease, Chronic Heart Failure) and/or Chronic Kidney Disease, and has had other serious cardiovascular conditions (e.g, heart attack or stroke) in the last 6 months
Patient has history of endocrine gland cancers or pancreatic cancers
Patient is undergoing chemotherapy or immunotherapy treatment in last 6 months
Patient's medical record contains ICD-10 Code for Type I diabetes diagnosis.
Patient's medical record contains ICD-10 Code for pregnancy-related diabetes:
024.419 (gestational diabetes)
024.419 (antepartum gestational diabetes)
Z79.4 (type II long term insulin use)
024.91x (pregnant women who are diabetic)
Patient is Pre-diabetic or borderline Type 2 diabetic
Patient is pregnant or lactating
Patient's electronic medical history data is not available through Penn Medicine's electronic medical record and/or is not complete in Penn Data Store
Patients who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Linda Fleisher, PhD, MPH
Organizational Affiliation
Children's Hospital of Philadelphia
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Reaching Better Health Study: A Website to Improve Type 2 Diabetes Self-Management
We'll reach out to this number within 24 hrs